Research Notes

Lupus Discovery May Result in Promising Therapy

Lupus Discovery May Result in Promising Therapy

Einstein researchers and their colleagues have found a key cause of severe kidney complications affecting many patients with lupus, an inflammatory autoimmune disease, and are evaluating a promising treatment for preventing those complications.

Up to half of all lupus patients will develop lupus-related kidney inflammation, known as lupus nephritis. Left unchecked, lupus nephritis can cause irreversible kidney scarring that can result in organ failure and death.

Immune cells known as T cells contribute significantly to lupus kidney damage by infiltrating and inflaming kidney tissue. In a study published online in January 2022 in the Journal of Clinical Investigation, a team led by senior author Chaim Putterman, M.D., professor of medicine and of microbiology & immunology at Einstein, found that these T cells are activated by a protein called ALCAM, which is expressed by various tissues in the body.

In a phase 1 clinical trial, Dr. Putterman and colleagues are treating lupus patients with itolizumab, a novel monoclonal antibody that specifically prevents ALCAM from binding to and activating kidney-damaging T cells. Dr. Putterman is also the associate dean for research at the Azrieli Faculty of Medicine at Israel’s Bar-Ilan University.

More From Einstein

Preparing New Grads for Hospital Roles
Einstein Celebrates 65th Commencement
Class of 2027 Receives White Coats
Mentoring in Medicine Paves Way for Success
Biomedical Sciences Leadership Program Begins
Einstein, Lehman Launch M.S. Program
2023 National Diversity Award
Health Equity Scholarship Honors Nilda Soto
Longevity Gene Project Awarded $13.6M


Campus News
Research Notes
Motivations: Donors & Alumni
More From This Issue

Past Issues

Download Magazine



  • This field is for validation purposes and should be left unchanged.